Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05089448

Morning Versus Bedtime Dosing of Antihypertensive Medication

Previous studies have shown that elevated nighttime blood pressure (BP) was more closely associated with cardiovascular mortality and morbidity than daytime and clinic BPs. With increasingly advanced technology, not only 24-hour ambulatory but also home BP monitors can be used to evaluate nighttime BP. The validation study of the Omron HEM 9601T showed that the wrist-type home BP monitor could be a suitable and reliable tool for the diagnosis and management of nocturnal hypertension. However, up to now, there is no data on home nighttime BP in Chinese patients and it is unclear if different dosing time would reduce ambulatory and home nighttime BPs differently.

The investigators therefore designed a multicenter randomized clinical trial to compare between morning dosing and bedtime dosing of antihypertensive medications in the difference in nighttime, daytime and the 24-h BP reductions evaluated by both ambulatory and home BP monitoring, and in target organ protections.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ruijin Hospital

Shanghai, Shanghai Municipality, 200025, China

Location status: Recruiting

Location contact

Yan Li, Professor

CONTACT

[email protected]

021-64370045 ext. 663228

Yan Li, Professor

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients aged 18-70 years old;
  • Never treated for hypertension or stopped using antihypertensive drugs for at least 2 weeks;
  • In the two screenings,the clinical systolic BP should be in the range of 140-159 mmHg, the diastolic BP < 100 mmHg;
  • The average 24-hour systolic BP ≥130mmHg, daytime systolic BP ≥ 135 mmHg, and nighttime systolic BP ≥ 120 mmHg;
  • The average of bilateral brachial-ankle pulse wave velocity ≥14m/s;
  • Be willing to participate in the trial, sign the informed consent form, and be able to visit doctors by himself or herself.

Exclusion criteria

  • Secondary hypertension;
  • Concomitant obstructive sleep apnea (STOP-BANG score ≥ 5), insomnia, Parkinson's syndrome, or nocturnal polyuria and other diseases that affect nighttime BP;
  • Need to work at night;
  • Ambulatory BP monitoring was invalid (<70% valid readings, or <20 daytime readings or <7 nighttime readings);
  • Concomitant diseases that need taking medications influencing BP;
  • Coronary heart disease, myocardial infarction or stroke within recent 6 months;
  • Atrial fibrillation or frequent arrhythmia;
  • Abnormal liver function exemplified as an increased alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBL) over the double of the upper limit of normal range; abnormal renal function exemplified as a serum creatinine ≥176 µmol/L; and plasma potassium ≥5.5 mmol/L or ≤3.5mmol/L;
  • Pregnant or lactating women;
  • Contraindications of angiotensin II receptor blocker or calcium channel blocker;
  • Other concomitant diseases which are considered not suitable to participate in the trial, such as thyroid diseases, acute infectious diseases, chronic mental diseases, tumor, etc.

Treatment and study plan

Alisartan, Amlodipine besylate

Drug

Drugs will be taken once daily at 6:00-10:00.

Primary outcomes

  1. Nighttime systolic BP reduction in mmHg

    Time frame: 24 weeks

    The difference between the morning and bedtime dosing groups in nighttime systolic BP reduction in mmHg measured by the ambulatory BP monitoring after the treatment for 24 weeks

Secondary outcomes

  1. Daytime systolic BP reduction in mmHg, 24-Hour systolic BP reduction in mmHg, Home systolic BP reduction in mmHg

    Time frame: 24 weeks

    The difference between the morning and bedtime dosing groups in the daytime and 24-hour systolic BPs reduction in mmHg measured by the ambulatory BP monitoring and home systolic BP reduction in mmHg after treatment for 24 weeks

  2. Brachial-ankle pulse wave velocity reduction in cm per second

    Time frame: 12 and 24 weeks

    The difference between the morning and bedtime dosing groups in reduction of brachial-ankle pulse wave velocity after treatment for 12 and 24 weeks

  3. Ambulatory night-to-day BP ratio change in percent; proportions of non-dippers in percent, morning systolic blood pressure in mmHg,

    Time frame: 8 weeks and 24 weeks

    The difference between the morning and bedtime dosing groups in change of Ambulatory night-to-day BP ratio change in percent; proportions of non-dippers in percent, and morning systolic blood pressure in mmHg after treatment for 8 and 24 weeks.

  4. Urinary albumine-to-creatinine ratio change in mg/mmol

    Time frame: 12 weeks and 24 weeks

    The difference between the morning and bedtime dosing groups in change of microalbumine-to-creatinine ratio in random urine samples after treatment for 12 weeks and 24 weeks

  5. change in prevalence of left ventricular hypertrophy defined based on electrocardiogram

    Time frame: 12 weeks and 24 weeks

    The difference between the morning and bedtime dosing groups in the change in prevalence (percentage) of left ventricular hypertrophy defined based on Cornell product and Sokolow-Lyon index in electrocardiogram after treatment for 12 weeks and 24 weeks

  6. change in prevalence of left ventricular hypertrophy defined based on echocardiography

    Time frame: 24 weeks

    prevalence (percentage) of left ventricular hypertrophy defined based on left ventricular mass index assessed by echocardiography after treatment for 24 weeks

  7. Serum uric acid in umol/L

    Time frame: 24 weeks

    The difference between the morning and bedtime dosing groups in serum uric acid in umol/L after treatment for 24 weeks

  8. The difference in daytime systolic and diastolic BPs between the ambulatory and home BP monitoring at baseline and after treatment for 24 weeks

    Time frame: 24 weeks

    The difference in daytime systolic and diastolic BPs between the ambulatory and home BP monitoring at baseline and after treatment for 24 weeks

  9. The difference in nighttime systolic and diastolic BPs between the ambulatory and home BP monitoring at baseline and after treatment for 24 weeks

    Time frame: 24 weeks

    The difference in nighttime systolic and diastolic BPs between the ambulatory and home BP monitoring at baseline and after treatment for 24 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Li Yan, Professor

CONTACT

[email protected]

021-64370045 ext. 663228

Sponsors and collaborators

Lead sponsor

Yan Li

Other

Registry information

Official study title

Morning Versus Bedtime Dosing of Antihypertensive Medication in Grade 1 Day-night Hypertension: a Multicenter Randomized Controlled Trial (Dosing-Time Trial)

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Oct 22, 2021
Registry last updated
Jan 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.